

A protein-engineering tour of Cambridge, MA

Shaun Lippow

Aileron Therapeutics
Merrimack Pharmaceuticals
Flagship Ventures

Codon Devices




Outline

- AILERON
 - Stapled helical peptides
- Electrostatics in protein–protein binding
 - A comparison of PB and Rosetta

Sorry, Aileron didn't want their slides distributed

Electrostatic free energy as a predictor of binding improvement




Fixbb; Rotamer library; DEE; CHARMM + PBelec
Antibody/antigen interfaces; Single mutations
Many predictions at periphery


How about Rosetta??

- Periphery (surface-like)
- Highly polar interface

wild-type Gly




mutation to Trp



$\Delta \Delta G_i$	vdW	nonpolar	elec.	Total		Exp.
(kcal/mol)	-7.0	-0.6	+2.7	-4.9		0.0

Rosetta: “polyTrp surface”; “just adding atoms”...


Large residues dominate predictions



Rosetta: “polyTrp surface”; “just adding atoms”...

S.M. Lippow, K.D. Wittrup, B. Tidor (2007) *Nat. Biotechnol.* 25 (10): 1171-1176


Predictions based on improved




Single mutations validated

Rosetta “elec” terms:
sol + hbnds + pair


Combinations of single mutations yield 100-fold improvement to 43 pM



Two mechanisms lead to 100-fold improved quadruple mutant



Electrostatic free energy as a predictor of binding improvement



**Rosetta: similar failure for periphery mutations
similar success with subset of electrostatic terms
(except mutations utilizing medium-range electrostatics)**

Acknowledgments

- MIT antibody design
 - Tidor Lab
 - Karl Hanf
 - David Green
 - Michael Altman
 - Alessandro Senes
 - Brian Joughin
 - Bruce Tidor
 - Wittrup Lab
 - Stefan Zajic
 - Daša Lipovšek
 - Wai Lau
 - Dane Wittrup
- AILERON
 - Scientific team
 - Nori Kawahata
 - Justin Noehre
 - Patricia Soulard
 - Management team
 - Joseph Yanchik III
 - Tomi Sawyer
 - Huw Nash
 - Rosana Kapeller
 - Allen Annis

Future work

- It depends!
 - Reduce my 4-body “problem” to a 2-body problem

